NRSN Neurosense Therapeutics Ltd
Company Analysis
Latest News
🔴 Neurosense Therapeutics is trading 9.1% down on October 22 amid a sharp broader-market selloff
Neurosense Therapeutics is trading at $2.33, down 9.12%, amid a sharply lower broader market. - The price was recorded at 10:50 a.m. EST on October 22, 2026. -...
🟢 Neurosense Therapeutics is trading 12.4% up today amid biotech strength, with no direct catalyst confirmed
Neurosense Therapeutics is trading at $2.63, up +12.39%, alongside biotech-sector strength, though no direct company-specific catalyst was confirmed for the...
🟢 Neurosense Therapeutics is trading 19.66% up in pre-market, with no confirmed company-specific catalyst
Neurosense Therapeutics is trading 19.66% up in pre-market at $2.80, with biotech-sector strength reported as supportive context but not a confirmed direct...
🟢 Neurosense Therapeutics is trading 9.83% up in pre-market with sector support; cause remains unclear
Neurosense Therapeutics is trading $2.57, up 9.83% in pre-market, with biotech-sector strength providing support while the specific trigger remains unclear. -...
🟢 Neurosense Therapeutics is trading 32.48% up in after-hours trading
Neurosense Therapeutics is trading at $3.10, up +32.48% in after-hours trading; no verified company-specific catalyst was identified for October 20, 2026. -...
🔴 Neurosense Therapeutics is trading 13.68% down in after-hours trading
Neurosense Therapeutics is trading at $2.02, down 13.68% in after-hours trading, with no verified company-specific catalyst identified. - On October 20, it...
🔴 Neurosense Therapeutics is trading 13.88% down with no verified company-specific catalyst identified
Neurosense Therapeutics is trading at $2.29, down 13.88%, with no verified company-specific catalyst identified for the October 20 decline. - October 19 news...
🔴 Neurosense Therapeutics is trading 10% down today — no verified company-specific catalyst
Neurosense Therapeutics is trading 9.94% lower at $2.40, with no verified company-specific catalyst for the October 20 decline. - The company’s October 19...
🟢 Neurosense Therapeutics is trading 8.4% up in pre-market
Neurosense Therapeutics is trading at $2.89, up +8.44% in pre-market, with no verified company-specific catalyst explaining the gain. - On October 19, the...
🔴 Neurosense Therapeutics is trading 6.6% down in pre-market on October 20, 2026 amid biotech weakness
Neurosense Therapeutics is trading at $2.49, down 6.57% in pre-market, with no verified company-specific catalyst identified. - The October 19 U.S. patent...
🔴 Neurosense Therapeutics is trading 5.8% down in after-hours trading with no verified company-specific catalyst
Neurosense Therapeutics is trading at $2.51, down -5.82% in after-hours trading, with no verified company-specific catalyst linked to the decline. -...
🔴 Neurosense Therapeutics is trading 11.1% down
Neurosense Therapeutics is trading 11.1% lower at $2.73, with no verified company-specific catalyst linked to the decline. - The company announced an October...
🔴 Neurosense Therapeutics is trading 8% down on October 19
Neurosense Therapeutics is trading 7.98% down at $2.83, with no verified company-specific catalyst tied to the decline. - An October 19 headline reported a...
🔴 Neurosense Therapeutics is trading 5.5% down in after-hours trading
Neurosense Therapeutics is trading 5.5% lower at $2.90 after closing at $3.07 in the October 16 regular session; no clear company-specific catalyst was...
🟢 Neurosense Therapeutics is trading 6.15% up today — no clear catalyst identified
Neurosense Therapeutics is trading at $3.19, up 6.15%, with no clearly linked catalyst identified for the October 16 move. - Available coverage showed no...
🔴 Neurosense Therapeutics is trading 13% down amid unresolved Nasdaq appeal
Neurosense Therapeutics is trading 12.61% lower at $3.05; no confirmed overnight company announcement directly explains the intraday drop. - Its Nasdaq appeal...
🔴 Neurosense Therapeutics is trading 5.4% down in pre-market with no confirmed overnight catalyst
Neurosense Therapeutics is trading 5.4% lower at $3.30 in pre-market, with no specific overnight catalyst established. - The company announced October 13 that...
🔴 Neurosense Therapeutics is trading 18.3% down in after-hours trading — no specific cause established
Neurosense Therapeutics is trading at $2.85, down 18.34% in after-hours trading; available evidence does not establish a specific cause. - Nasdaq appeal...
NeuroSense Buys Time on Nasdaq, but Can a $13 Million Biotech Close a $35 Million Gap Before the Clock Runs Out?
Shares of NeuroSense Therapeutics surged 13.2% to $3.95 after the company disclosed that a Nasdaq Hearings Panel will review its delisting appeal on November...
🟢 Neurosense Therapeutics is trading 13.2% up in after-hours trading amid Nasdaq appeal update
Neurosense Therapeutics is trading 13.2% up at $3.95 after closing at $3.49 on October 13; the Nasdaq update is a plausible company-specific catalyst, but the...